![IgG (Kappa light chain) Goat anti-Human, Secondary Antibody, Invitrogen™ 1 mg; Unconjugated Anticuerpo secundario de cabra anti-IgG humana | Fisher Scientific IgG (Kappa light chain) Goat anti-Human, Secondary Antibody, Invitrogen™ 1 mg; Unconjugated Anticuerpo secundario de cabra anti-IgG humana | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/LSG/antibodies/SA5-10285-HRP-Sheep-anti-Goat-IgG-h-l-ELISA-1-20200620092909.jpg-650.jpg)
IgG (Kappa light chain) Goat anti-Human, Secondary Antibody, Invitrogen™ 1 mg; Unconjugated Anticuerpo secundario de cabra anti-IgG humana | Fisher Scientific
![IgG (Kappa light chain) Rat anti-Mouse, HRP, Invitrogen™ 250 μg; HRP Primary Antibodies Ia to IgF | Fisher Scientific IgG (Kappa light chain) Rat anti-Mouse, HRP, Invitrogen™ 250 μg; HRP Primary Antibodies Ia to IgF | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/LSG/figures/MA1-34732-Rat-anti-Mouse-IgG1-Secondary-Antibody-HRP-WB-20170221143928.jpg-650.jpg)
IgG (Kappa light chain) Rat anti-Mouse, HRP, Invitrogen™ 250 μg; HRP Primary Antibodies Ia to IgF | Fisher Scientific
![Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern | Fluids and Barriers of the CNS Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern | Fluids and Barriers of the CNS](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F2045-8118-9-5/MediaObjects/12987_2011_Article_32_Fig2_HTML.jpg)
Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern | Fluids and Barriers of the CNS
![Vista de Inmunofijación: más allá de la tipificación de gammapatías monoclonales. Valor pronóstico, categorización de respuesta al tratamiento e importancia en la detección de interferencias por el uso de anticuerpos monoclonales terapéuticos Vista de Inmunofijación: más allá de la tipificación de gammapatías monoclonales. Valor pronóstico, categorización de respuesta al tratamiento e importancia en la detección de interferencias por el uso de anticuerpos monoclonales terapéuticos](http://revistahematologia.com.ar/index.php/Revista/article/download/464/version/336/657/3289/image009.gif)